Journal Home
Search for

Volume 584, Issue 5, Pages 873-877 (5 March 2010)


View previous. 7 of 41 View next.

Myeloid translocation gene 16b is a dual A-kinase anchoring protein that interacts selectively with plexins in a phospho-regulated manner

Edited by Beat Imhof

Sarah E. Fiedlera, Robynn V. Schillaceab, Crystal J. Danielsa, Sarah F. Andrewsa, Daniel W. CarraCorresponding Author Informationemail address

Received 31 December 2009; accepted 1 February 2010. published online 05 February 2010.

Abstract 

The myeloid translocation gene (MTG) homologue Nervy associates with PlexinA on the plasma membrane, where it functions as an A-kinase anchoring protein (AKAP) to modulate plexin-mediated semaphorin signaling in Drosophila. Mammalian MTG16b is an AKAP found in immune cells where plexin-mediated semaphorin signaling regulates immune responses. This study provides the first evidence that MTG16b is a dual AKAP capable of binding plexins. These interactions are selective (PlexinA1 and A3 bind MTG, while PlexinB1 does not) and can be regulated by PKA-phosphorylation. Collectively, these data suggest a possible mechanism for the targeting and integration of adenosine 3′,5′-cyclic monophosphate (cAMP) and semaphorin signaling in immune cells.

Structured summary

MINT-7556975: PlexinA3 (uniprotkb:P51805) physically interacts (MI:0915) with MTG 16b (uniprotkb:O75081) by anti tag coimmunoprecipitation (MI:0007)

MINT-7557008: RI alpha (uniprotkb:Q9DBC7) physically interacts (MI:0915) with MTG 16b (uniprotkb:O75081) by anti bait coimmunoprecipitation (MI:0006)

MINT-7556989: MTG 16b (uniprotkb:O75081) physically interacts (MI:0915) with PlexinA3 (uniprotkb:P51805) by pull down (MI:0096)

Article Outline

Abstract

1. Introduction

2. Materials and methods

2.1. Vector constructs

2.2. Transformation, expression and pulldown assays

2.3. Transfection and immunoprecipitation (IP) and immunoblot (IB)

2.4. Phosphorylation

3. Results/discussion

3.1. MTG interacts with plexins

3.2. MTG is a dual AKAP

3.3. MTG complexes with plexin and RI

3.4. Phosphorylation affects MTG interactions with RI and plexins

4. Conclusion

Acknowledgment

Appendix A. Supplementary data

References

Copyright

1. Introduction 

return to Article Outline

Agents that activate the adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent second messenger pathway are potent inhibitors of T-cell activation [1], [2]. While numerous reports document the effectiveness of cAMP as an anti-inflammatory agent, the molecular mechanisms producing these effects are still under investigation. This lack of knowledge has thwarted progress toward clinical application of therapies that target cAMP. A-kinase anchoring proteins (AKAPs) are defined by their ability to bind one or more of the regulatory subunits (type I: RIα and RIβ and type II: RIIα and RIIβ) of cAMP-dependent protein kinase A (PKA). These subunits interact with an amphipathic helix domain on the AKAP. AKAPs target the action of PKA signaling by acting as scaffolding proteins, spatially restricting function by simultaneously binding related signal transduction enzymes [3], [4]. We have identified seven different AKAPs in T lymphocytes and dendritic cells, including the discovery of a novel AKAP, myeloid translocation gene (MTG) [4], [5]. MTG was originally identified as a fusion protein with AML in patients with acute myeloid leukemia and has been detected in the nucleus, cytoplasm and Golgi [6]. MTG acts as an regulatory subunit of type II PKA (RII) binding AKAP and is thus a potential adaptor protein for cAMP signaling in immune response [4], [7]. However, a growing body of evidence suggests that the type I PKA isoforms may play a greater role in regulating the immune response; mice lacking RIIα have normal immune responses to cAMP, type I regulatory subunits co-localize with the TCR during T-cell activation [8], and activation of PKA type I alpha alone is sufficient for cAMP-dependent immunosuppression [9]. Thus, it would be interesting to determine whether MTG is a dual AKAP.

Controlling the concentration of cAMP and the activity of PKA is crucial for directing an axon to its proper target [10]. Insight into how cAMP dictates axonal steering responses has been gained from the discovery that Nervy, a Drosophila AKAP with significant homology to MTG, couples plexin to PKA to modulate semaphorin repulsion. Work by Terman and Kolodkin illustrates that Nervy associates with PlexinA on the plasma membrane. Nervy functions as an AKAP and modulates intracellular signaling initiated by the interaction of semaphorins and plexins [11]. This finding suggests a mechanism for the integration of diverse signaling inputs to the axonal growth cone [11], [12].

The immune and nervous systems are similar in many respects. Both are highly networked systems that interact using shared molecules such as chemical mediators and cytokines [13]. T-cells and antigen presenting cells (APCs) form a unique cellular architecture at their contact zone (the immunological synapse) that is structurally similar to the neurological synapse [14]. Several semaphorins have been detected in cells of the immune system and have been shown to be key regulatory molecules controlling the immune response, reviewed in [13], [15], [16], [17]. The plexin and neurophilin families of semaphorin receptor proteins are also expressed by a variety of immune cells and are involved in semaphorin signaling in the immune system [16], [18], [19], [20], [21], [22].

In this study, we investigate whether mammalian proteins MTG16b and plexins can interact. Results indicate that MTG binds selectively to plexins, and that this binding can be regulated by PKA-phosphorylation. Additionally, we determine that MTG is a dual AKAP, capable of binding both regulatory subunit of type I PKA (RI) and RII. Taken together, these data indicate that MTG16b has the potential to scaffold cAMP and semaphorin signaling in immune cells.

2. Materials and methods 

return to Article Outline

2.1. Vector constructs 

Preparation of MTG16b constructs is described previously [4], [23]. Constructs expressing full-length human PlexinA3-pcDNA, PlexinB1-pcDNA, and human/mouse chimera PlexinA1-pcDNA (all VSV-G tagged) were kindly provided by Dr. Luce Tamagnone. For bacterial expression, restriction enzyme digestion was used to obtain just the cytoplasmic domain of each plexin: XhoI for PlexinA1, EcoRI and NcoI for PlexinA3 and EcoRI for PlexinB1. Fragments were ligated into pET30 (S-protein-tagged) or pGEX-5X [glutathione S-transferase (GST)-tagged]. For PlexinA3 cloning into pGEX-5X, primers were designed to add BamHI and NotI restriction sites, respectively: forward 5′-CGCGGATCCATGCCATGGTGGCCCTGCAGAGC-3′ and reverse 5′-ATAAGAATGCGGCCGCCCTCCTCACCGATTCCACCAC-3′. Due to poor protein expression using PlexinB1-pcDNA to transfect COS7 cells, PlexinB1 was also expressed in pEGFP (cut from pcDNA construct as above).

2.2. Transformation, expression and pulldown assays 

Methods for transformation, bacterial protein induction and expression, and pulldown assays are described previously [24].

2.3. Transfection and immunoprecipitation (IP) and immunoblot (IB) 

Transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as described previously [24], using 2.5μg of MTG-pcDNA (myc-his tagged) and 5μg of plexin-pcDNA (VSV-G tagged). Immunoprecipitation and immunoblot methods are described in [24], with modifications. Briefly, a glycerol lysis buffer was used (20mM Tris–HCl pH 7, 4, 5mM EDTA, 150mM NaCl, 10% glycerol, 1% Triton-X 100, and protease inhibitors as in [24]. IP antibodies were: rabbit polyclonal anti-VSV-G (8μg; Sigma–Aldrich, St. Louis, MO), mouse monoclonal anti-myc (10μg; Santa Cruz Biotechnology, Santa Cruz, CA; used to IP MTG rather than PlexinB1-GFP in co-IP experiments due to the myc antibody′s superior performance in IP assays compared to the green fluorescent protein (GFP) antibody), or mouse monoclonal anti-RI (4μg, BD Biosciences, San Jose, CA). Isotype appropriate IgG (all BD Biosciences) in amounts equal to IP antibody was used as a negative control in each IP. IB antibodies were VSV-G (1:2000), myc (1:500), RI (1:300), and rabbit polyclonal anti-GFP (1:250; Clontech, Mountain View, CA). Genscript (Piscataway, NJ) One Hour IP Western Kit was used according to manufacturer′s instructions for RI western blots to minimize interference from IP/IgG cross reaction with the IB antibody.

2.4. Phosphorylation 

Phosphorylation for pulldown experiments is described in [3].

3. Results/discussion 

return to Article Outline

Unless otherwise specified, proteins in this section are recombinant and tagged to facilitate IPs and IBs. Appropriate controls are included to ensure that binding is specific to the protein and not the tags. See figure legends for detail.

3.1. MTG interacts with plexins 

To determine whether MTG interacts with plexins, two types of binding assays were performed. Co-immunoprecipitation experiments using co-transfected COS7 cells revealed that full-length (FL) MTG interacts with plexins A1 and A3, but not PlexinB1 (Fig. 1A, compare lane 3 in upper panels). To confirm the results of IP experiments using a second method, to delineate the binding domains involved, and to examine the effects of phosphorylation on binding, MTG16b (FL and fragments: amino acids 200–700, 700–1510, and 1510–2000) was bacterially expressed. Due to the fact that MTG is not a membrane or extracellularly expressed protein, we hypothesized that it would interact with the highly conserved cytoplasmic domain of plexins [4]. As such, we subcloned and expressed just the cytoplasmic domains (C1 and C2) of plexins A1, A3 and B1. Consistent with co-immunoprecipitation assays, the cytoplasmic domains plexins A1 and A3 bound to FL MTG16b, while PlexinB1 did not (Fig. 1B, compare lane 3 in upper panels). Interestingly, in fragment pulldowns, plexins A1 and A3 bound well to FL MTG, but they both bound only weakly and inconsistently to the MTG fragments (primarily binding to the 200–700 and 700–1510 fragments, data not shown). This may indicate that proper folding of the intact FL MTG protein is required for optimal binding of plexins.


View full-size image.

Fig. 1. MTG interacts with PlexinA1 and PlexinA3, but not PlexinB1. (A) COS7 cells were co-transfected with full-length MTG-pcDNA(myc-His) and PlexinA1-pcDNA, PlexinA3-pcDNA (both VSV-G tagged), or PlexinB1-pEGFP. Lane 1 in all panels is a lysate control for transfection. In the PlexinA1 and PlexinA3 panels, immunoprecipitations (IP) were performed with negative control IgG (lane 2) or VSV-G polyclonal antibody (lane 3). After SDS-PAGE and transfer, membranes were cut in half and immunoblotted (IB) with anti-VSV-G antibody to confirm IP (top panel), or anti-myc antibody (bottom panel), demonstrating that MTG co-IP with plexins A1 and A3. In the PlexinB1 panel, IPs were performed with negative control IgG (lane 2) or anti-myc monoclonal antibody (lane 3). Anti-myc antibody IB was performed to confirm IP, and polyclonal anti-GFP antibody IB was performed, demonstrating that MTG does not co-IP with PlexinB1. (B) Pulldown assays using bacterially expressed proteins and glutathione sepharose (GST) beads. Lane 1 in each panel is the plexin-S tagged protein. Plexin-S tagged protein lysates were incubated with GST beads alone (data not shown), GST beads bound to GST lysates (lane 2), or MTG-GST lysates (lane 3). Western analysis was used to detect binding of plexins (upper blot in each panel) to GST (lower blot in each panel). In (A) and (B) the results are representative blots of three independent experiments.


3.2. MTG is a dual AKAP 

We used co-IP and pulldown assasy to determine whether MTG interacts with RI. Co-IP experiments using MTG transfected COS7 cells revealed that MTG interacts with endogenously expressed RI (Fig. 2A). To confirm a direct interaction, purified RIα and MTG were used in pulldown assays. Consistent with co-immunoprecipitation assays, RIα interacts with FL MTG (Fig. 2B). Together with our previous studies that demonstrate RII-MTG interactions [4], these data indicate that MTG is a dual AKAP. This result is supported by recently published sequence analyses suggesting that in addition to the well-characterized RII-binding amphipathic helix domain, dual AKAPs contain a PKA binding region called the RI Specifier Region (RISR) [25]. Sequence alignment with the dual AKAPs presented in the Jarnaess study indicate that MTG16b contains the RISR motif (Supplementary data).


View full-size image.

Fig. 2. MTG interacts with RI. (A) COS7 cells were transfected with full-length MTG-pcDNA(myc-His). Lane 1 in both panels is a lysate control to demonstrate size and confirm transfection. IPs were performed with negative control IgG (lane 2) or RI monoclonal antibody (lane 3). After SDS-PAGE and transfer, membranes were cut in half and immunoblotted (IB) with anti-RI antibody to confirm IP (top panel), or anti-myc antibody (bottom panel) to demonstrate that MTG co-IPs with RI. Both IBs used Genscript’s (Piscataway, NJ) one-step IP Western blot kit. Since different antibodies are used, resulting bands should not be considered quantitative measures of protein. (B) Pulldown assays using S-protein beads. Lane 1 is RIα protein bacterial lysate compared to pulldown lanes 2 and 3. Bacterially expressed, affinity-purified RIα was incubated with S-protein beads alone (data not shown), S-protein beads bound to S-protein bacterial lysates (lane 2), or MTG-S protein bacterial lysates (lane 3). Western analyses with anti-RIα monoclonal antibody were used to detect RI binding. In (A) and (B) the results are representative blots of three independent experiments.


3.3. MTG complexes with plexin and RI 

In functioning as scaffolding proteins that target PKA-phosphorylation, AKAPs will often simultaneously bind the R subunits of PKA and PKA substrate(s) [23], [24]. To illustrate that MTG binds RIα and plexins concurrently, forming a signaling complex, we performed pulldown assays. Results indicate that MTG is capable of and necessary for forming a complex with plexins and RIα (Fig. 3, lane 2) as RIα and PlexinA3 do not interact directly (Fig. 3, lane 1).


View full-size image.

Fig. 3. MTG can form a complex with plexin and RIα. In modified pulldown assays, PlexinA3-GST was immobilized on GST beads and incubated with either negative control S-protein (lane 1) or MTG-S protein (lane 2). Both sets of beads were then washed and incubated with bacterially expressed, cAMP affinity-purified RIα (lanes 1 and 2). The samples were separated by SDS–PAGE, transferred to Immobilon PVDF membranes, and western blots were performed with anti-RIα monoclonal antibody and goat anti-mouse-HRP-conjugated secondary antibody in order to detect binding of RI (lower blot). Anti-GST-HRP and anti-S protein-HRP western blots were also performed in order to confirm loading of PlexinA3 (upper blot) and MTG (middle blot), respectively. These results are representative blots of three independent experiments.


3.4. Phosphorylation affects MTG interactions with RI and plexins 

Phosphorylation is a key event in many signaling pathways, often manifesting its effects by altering binding affinities. Recent studies have demonstrated regulation of AKAP protein interactions via PKA-phosphorylation of the AKAPs. Furthermore PlexinA, the drosophila plexin that interacts with MTG family member Nervy, may be a target for PKA-phosphorylation [3], [12]. In addition, tyrosine phosphorylation of plexins is important in semaphorin signaling [26]. As such, we performed studies to test the hypothesis that PKA-phosphorylation affects plexin/MTG/RI interactions. To begin, we performed experiments to determine the sites of PKA-phosphorylation on MTG, which are S536 and S411 (see Supplementary data).

Using FL MTG, purified RIα, and the cytosolic domains of PlexinA1 or PlexinA3 (see above), we performed pulldown assays to determine whether PKA-phosphorylation of either MTG or plexins alters interactions (RIα is constitutively phosphorylated in vivo). First, MTG was immobilized on beads and PKA-phosphorylated, plexins or purified RIα were added. Binding was compared to unphosphorylated MTG. Results indicate that PKA-phosphorylation of MTG significantly increases its interaction with PlexinA1, PlexinA3, and RIα (Fig. 4A). In reverse pulldowns, plexins were immobilized and PKA phosphorylated as above, then MTG was added. Results indicate that PKA-phosphorylation of PlexinA3 increases its interaction with MTG (Fig. 4B, right), while PKA-phosphorylation of PlexinA1 has no effect on its interaction with MTG (Fig. 4B, left).


View full-size image.

Fig. 4. PKA phosphorylation affects MTG interactions with plexins and RI. (A) MTG-S protein was immobilized on S-protein beads and either left unphosphorylated (bar 1 and lane 1 in each blot) or phosphorylated by the catalytic subunit of PKA (bar 2 and lane 2 in each blot). GST-PlexinA1 (left), GST-PlexinA3 (middle), or purified RIα (right) lysates were then incubated with the bead-bound MTG. Samples were electrophoresed, transferred and anti-GST-HRP western blots were performed to detect binding of the plexins or RIα to MTG. Phosphorylation of MTG by PKA resulted in a significant increase in binding to all proteins tested (PlexinA1 P=0.04, PlexinA3 P=0.02, and RIα P=0.02 by t-test; * denote significance). (B) PlexinA1-GST (left) or PlexinA3-GST (right) is immobilized on GST beads and either left unphosphorylated (bar 1 and lane 1 in each blot) or phosphorylated by the catalytic subunit of PKA (bar 2 and lane 2 in each blot). MTG-S protein lysate was then incubated with the bead-bound plexins. Western analysis detects binding of the MTG to plexins. Phosphorylation of PlexinA3 by PKA resulted in a significant increase in binding to MTG (P=0.01 by t-test, * denotes significance), while phosphorylation of PlexinA1 did not affect its interaction with MTG. The blots in A and B are each one representative of three separate experiments in which equal loading was determined by coomassie staining and western blot (anti-S protein-HRP, A, anti-GST-HRP, B). PKA-phosphorylation of proteins was confirmed using the anti-phospho-serine PKA substrate antibody. Densitometric analyses were performed using NIH Image software. Error bars are±S.E.M.


4. Conclusion 

return to Article Outline

In summary, this study provides the first evidence that MTG16b is a dual AKAP capable of binding plexins. Additionally, we report that these interactions are specific (PlexinA1 and A3 are bound, while PlexinB1 is not) and can be regulated by PKA-phosphorylation. Collectively, these data suggest a possible mechanism for the targeting and integration of cAMP and semaphorin signaling in immune cells.

Acknowledgements 

return to Article Outline

We thank Dr. Luce Tamagnone for providing us with plexin constructs. This research was supported by Merit Award from the Department of Veterans Affairs, Biomedical Laboratory Research & Development Service (DWC).

Appendix A. Supplementary data 

return to Article Outline


View full-size image.

Fig. S1. MTG contains an RI Specifier Region. Full-length human MTG16b protein sequence was aligned with the RI Specifier Region (RISR) of three dual AKAPs using MacVector 7.2 (ClustalW multiple sequence alignment; matrix: blosum, open gap penalty: 40, extended gap penalty: 0.05, pairwise alignment mode: slow, delay divergent: 50%, gap separation distance: and 8, with residue-specific and hydrophilic penalties), showing a potential MTG RISR motif at a.a. 425-454. Asterisks denote “functionally conserved” residues among dual specificity AKAPs (see Jarnaess et al. [25] for details).



View full-size image.

Fig. S2. PKA phosphorylates MTG16b at two sites. Scan site protein analysis predicts three sites of phosphorylation by PKA: 264–267, 408–411, and 533–536. (A) MTG16b or vector control (pcDNA3.1 myc/his) were transfected into COS cells. Cells were incubated in phosphate-free medium for 1h at 37°C then 32Pi was added for 3h at 37°C. The medium was removed; cells were rinsed with PBS and collected in lysis buffer by scraping. Lysates were rotated at 4°C and centrifuged to remove insoluble material. MTG16b was IP’d with an anti-myc antibody. IP samples were analyzed by SDS–PAGE and transferred to Immobilon-P (Millipore). Half the blot was exposed to X-ray film (left panel) while the other half was probed with anti-Myc antibody (right panel). These results illustrate that MTG16b is phosphorylated in vivo. (B) Fragments of MTG16b (amino acids 166–344 and 344–432) were expressed in bacteria as His and S-tag fusion proteins (pET30 vector). The proteins were purified from bacteria using His–tag affinity column chromatography by FPLC. Purified proteins were incubated with the PKA catalytic subunit (CSU) and 32P-ATP in (50mM MOPs, 100mM MgCl2, 0.25mg/ml BSA pH 7.0). Proteins were separated from free 32P-ATP by SDS–PAGE and transferred to Immobilon-P (Millipore). Half the blot was exposed to X-ray film (B, left panel) and half the blot was incubated with HRP-conjugated S-protein (right panel). As illustrated by S-protein recognition, both MTG16b fragments were present in roughly equal amounts; however, only fragment 344–432 was phosphorylated by PKA in vitro. Control experiments were performed using heat-inactivated CSU to confirm that phosphorylation resulted from PKA and not residual kinase activity in the protein prep (data not shown). (C) Eighteen amino acid peptides containing the predicted PKA-phosphorylation sites were synthesized onto cellulose paper using an Autospot Robot ASP222 (ABIMED, Langenfeld, Germany). Circles delineate the spots corresponding to each peptide. Peptide 481–498 from MAP (microtubule affinity regulating kinase) was used as a positive control and corresponding MTG peptides with the serine residue mutated to an alanine were used as a negative control. The upper panel shows peptides that were phosphorylated by CSU with 32P-ATP, washed and exposed to X-ray film for 1day. The middle panel shows peptides that were phosphorylated by CSU with non-radioactive ATP and detected using the PKA specific anti-phospho-serine antibody (anti-P PKA) (Cell Signaling, Beverly, MA). The bottom panel shows peptides incubated with the phosphorylation reaction in the absence of CSU and detected with the anti-P PKA antibody. These results show that in vitro PKA phosphorylates serines 536 and 411of MTG16b but not serine 267.


References 

return to Article Outline

[1]. [1]Schillace RV, Carr DW. The role of protein kinase A and A-kinase anchoring proteins in modulating T-cell activation: progress and future directions. Crit. Rev. Immunol. 2006;26:113–131. MEDLINE

[2]. [2]Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal. 2002;14:1–9. MEDLINE | CrossRef

[3]. [3]Fiedler SE, Bajpai M, Carr DW. Identification and characterization of RHOA-interacting proteins in bovine spermatozoa. Biol. Reprod. 2008;78:184–192. CrossRef

[4]. [4]Schillace RV, Andrews SF, Liberty GA, Davey MP, Carr DW. Identification and characterization of myeloid translocation gene 16b as a novel a kinase anchoring protein in T lymphocytes. J. Immunol. 2002;168:1590–1599. MEDLINE

[5]. [5]Schillace RV, Miller CL, Pisenti N, Grotzke JE, Swarbrick GM, Lewinsohn DM, et al. A-kinase anchoring in dendritic cells is required for antigen presentation. PLoS One. 2009;4:e4807.

[6]. [6]Rossetti S, Hoogeveen AT, Sacchi N. The MTG proteins: chromatin repression players with a passion for networking. Genomics. 2004;84:1–9. MEDLINE | CrossRef

[7]. [7]Fukuyama T, Sueoka E, Sugio Y, Otsuka T, Niho Y, Akagi K, et al. MTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent protein kinase in lymphocytes. Oncogene. 2001;20:6225–6232. MEDLINE | CrossRef

[8]. [8]Skalhegg BS, Tasken K, Hansson V, Huitfeldt HS, Jahnsen T, Lea T. Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science. 1994;263:84–87. MEDLINE

[9]. [9]Skalhegg BS, Landmark BF, Doskeland SO, Hansson V, Lea T, Jahnsen T. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J. Biol. Chem. 1992;267:15707–15714. MEDLINE

[10]. [10]Song HJ, Poo MM. Signal transduction underlying growth cone guidance by diffusible factors. Curr. Opin. Neurobiol. 1999;9:355–363. MEDLINE | CrossRef

[11]. [11]Terman JR, Kolodkin AL. Nervy links protein kinase a to plexin-mediated semaphorin repulsion. Science. 2004;303:1204–1207. CrossRef

[12]. [12]Bashaw GJ. Semaphorin signaling unplugged; a nervy AKAP cAMP(s) out on plexin. Neuron. 2004;42:363–366. MEDLINE | CrossRef

[13]. [13]Kikutani H, Kumanogoh A. Semaphorins in interactions between T cells and antigen-presenting cells. Nat. Rev. Immunol. 2003;3:159–167. MEDLINE

[14]. [14]Dustin ML, Colman DR. Neural and immunological synaptic relations. Science. 2002;298:785–789. CrossRef

[15]. [15]Takegahara N, Kumanogoh A, Kikutani H. Semaphorins: a new class of immunoregulatory molecules. Philos. Trans. Royal Soc. Lond. B: Biol. Sci. 2005;360:1673–1680.

[16]. [16]O’Connor BP, Ting JP. The evolving role of semaphorins and plexins in the immune system: Plexin-A1 regulation of dendritic cell function. Immunol. Res. 2008;41:217–222. CrossRef

[17]. [17]Moretti S, Procopio A, Boemi M, Catalano A. Neuronal semaphorins regulate a primary immune response. Curr. Neurovasc. Res. 2006;3:295–305. MEDLINE

[18]. [18]Takegahara N, et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat. Cell Biol. 2006;8:615–622. MEDLINE | CrossRef

[19]. [19]Tordjman R, Lepelletier Y, Lemarchandel V, Cambot M, Gaulard P, Hermine O, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat. Immunol. 2002;3:477–482. MEDLINE

[20]. [20]Walzer T, Galibert L, De Smedt T. Dendritic cell function in mice lacking Plexin C1. Int. Immunol. 2005;17:943–950. MEDLINE | CrossRef

[21]. [21]Wong AW, et al. CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nat. Immunol. 2003;4:891–898. MEDLINE | CrossRef

[22]. [22]Yamamoto M, et al. Plexin-A4 negatively regulates T lymphocyte responses. Int. Immunol. 2008;20:413–420. CrossRef

[23]. [23]Asirvatham AL, Galligan SG, Schillace RV, Davey MP, Vasta V, Beavo JA, et al. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J. Immunol. 2004;173:4806–4814. MEDLINE

[24]. [24]Bajpai M, Fiedler SE, Huang Z, Vijayaraghavan S, Olson GE, Livera G, et al. AKAP3 selectively binds PDE4A isoforms in bovine spermatozoa. Biol. Reprod. 2006;74:109–118. MEDLINE | CrossRef

[25]. [25]Jarnaess E, Ruppelt A, Stokka AJ, Lygren B, Scott JD, Tasken K. Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J. Biol. Chem. 2008;283:33708–33718. CrossRef

[26]. [26]Franco M, Tamagnone L. Tyrosine phosphorylation in semaphorin signalling: shifting into overdrive. EMBO Rep. 2008;9:865–871. CrossRef

a VA Medical Center and Department of Endocrinology, Oregon Health & Sciences University, Portland, OR, USA

b VA Medical Center and Department of Neurology, Oregon Health & Sciences University, Portland, OR, USA

Corresponding Author InformationCorresponding author. Address: Veterans Affairs Medical Center, Mail Code R&D 8, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA. Fax: +1 503 721 1082.

PII: S0014-5793(10)00101-8

doi:10.1016/j.febslet.2010.02.007


View previous. 7 of 41 View next.